Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00512889 · ClinicalTrials.gov registry record · Phase 1
Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00512889: Completed Phase 1 study, sponsored by Dana-Farber Cancer Institute.
NCT00512889 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00512889, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Cytotoxic T lymphocytes (CTL) are cells of the immune system that can fight infections and cancer. These CTL can be manipulated in the laboratory so that they can target an individual's cancer. PURPOSE: This early phase trial is studying the feasibility and side effects of intravenous infusions of CTL generated in the laboratory. To produce the CTL, the study participant's own immune cells are collected by a procedure called a leukapheresis. The cells then undergo laboratory processing for three weeks. Part of this processing includes mixing the patients immune cells with a new kind of cell that has some extra genes added to it. These extra genes are to "teach" the participant's own immune cells to become anti-tumor CTL that can attack the melanoma.
Interventions
- DRUG GM-CSF
- BIOLOGICAL therapeutic autologous lymphocytes
- GENETIC Use of an artificial antigen presenting cell (aAPC) to generate CTL
- RADIATION Irradiation of cutaneous tumor lesion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2007-08 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
What the finished NCT00512889 record still lists
NCT00512889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 4 interventions - of which GM-CSF is the first listed.
NCT00512889 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00512889 about?
NCT00512889 is a clinical study titled "Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma". RATIONALE: Cytotoxic T lymphocytes (CTL) are cells of the immune system that can fight infections and cancer. These CTL can be manipulated in the laboratory so that they can target an individual's cancer. PURPOSE: This early phase trial is studying the feasibility and side effects of intravenous in...
What is the current status of trial NCT00512889?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2007-08. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00512889?
The interventions under investigation include: GM-CSF (DRUG), therapeutic autologous lymphocytes (BIOLOGICAL), Use of an artificial antigen presenting cell (aAPC) to generate CTL (GENETIC), Irradiation of cutaneous tumor lesion (RADIATION).
Who is sponsoring clinical trial NCT00512889?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00512889's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia